Covipiravir

COVIPIRAVIR

COMPOSITION :

Each capsule contains :

– Monulpiravir …………………………………………………………..: 200 mg

– Excipients : q.s…………………………………………………………..One capsule

THERAPEUTIC PROPERTIES:

Antivirals for systemic use

 INDICATIONS :

– Molnupiravir is indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adult with a positive SARS-COV-2 diagnostic test).

CONTRAINDICATION:

– Hypersensitivity to the active substance or to any of the excipient.

IN DOUBT CASE, IT IS ESSENTIAL TO SEEK THE ADVICE

FROM YOUR DOCTOR OR YOUR PHARMACIST.

PRECAUTION AND WARNING :

– Molnupiravir is not recommended during pregnancy.

– Based on the potential for adverse reaction on the infant from Molnupiravir, breast-feeding is not recommended during treatment and for 4 days after the last dose of Molnupiravir.

SIDE EFFECTS:

-Dizziness, Headache, Diarrhoea, nausea, vomiting, rash, urticarial.

DOSAGE AND ADMINIST

RATION

Oral route :

Reserve for Adult only :

– Take 4 Capsules (800mg) every 12 hours for 5 days.